Results 41 to 50 of about 1,993 (117)

Childhood internalising symptoms at ages 3 and 6: a meta‐analysis of epigenome‐wide associations from cord and peripheral blood

Journal of Child Psychology and Psychiatry, EarlyView.
Background Pre‐ and postpartum environments and genetic effects influence childhood internalising problems, which increase depression risk. DNA methylation (DNAm) may capture some of these effects. We therefore investigated associations between child blood DNAm and internalising problems.
Laura Schellhas, Mannan Luo, Janine F. Felix, Christian M. Page, Mona Bekkhus, Marcus R. Munafò, Luisa Zuccolo, Alexandra Havdahl, Charlotte A.M. Cecil, Gemma C. Sharp   +9 more
wiley   +1 more source

Lanreotide, a Somatostatin Analogue, in Advanced Merkel Cell Carcinoma: A Prospective Single‐Arm Phase II Study

Cancer Medicine, Volume 15, Issue 10, October 2026.
ABSTRACT Background Merkel Cell Carcinoma (MCC) is a rare, aggressive neuroendocrine and epithelial skin cancer. Somatostatin analogues, such as lanreotide, have shown efficacy in managing other neuroendocrine tumors. Retrospective studies suggest that lanreotide may induce partial response or disease stabilization in patients with advanced MCC.
Julie Charles, Aude Belbezier, Stéphane Mouret, Brigitte Dreno, Stéphane Dalle, Céleste Lebbe, Ewa Hainaut‐Wierzbicka, Andreea Stefan, Julie de Quatrebarbes, Olivier Dereure, Ouidad Zehou, Sandrine Mansard, Alain Dupuy, Caroline Dutriaux, Florent Grange, Caroline Gaudy‐Marqueste, Henri Montaudié, Jean‐Philippe Arnault, Yannick Le Corre, Thibault Kervarrec, Jean‐Louis Quesada, Mahtab Samimi, Marie‐Thérèse Leccia, The Group of Cutaneous Oncology of the French Society of Dermatology   +23 more
wiley   +1 more source

Long-term results of PRRT in advanced bronchopulmonary carcinoid

, 2016
Purpose: Peptide receptor radionuclide therapy (PRRT) for the treatment of neuroendocrine tumours (NET) has been explored for almost two decades, but there are still few trials that have exclusively investigated well-differentiated and moderately ...
Bodei, Lisa, Galetta, Domenico, Fazio, Nicola, Colandrea, Marzia, Gilardi, Laura, Tinelli, Carmine, Baio, Silvia Melania, Mariniello, Annapaola, Valmadre, Giuseppe, Papi, Stefano, PAGANELLI, Giovanni, Grana, Chiara Maria   +11 more
core   +1 more source

The Molecular and Immunological Landscape in Nasopharyngeal Carcinoma (NPC) Differs by Somatostatin Receptor 2 (SSTR2) Expression

Cancer Medicine, Volume 15, Issue 9, September 2026.
ABSTRACT Somatostatin receptor 2 is expressed in nasopharyngeal carcinoma (NPC). We report genomic and transcriptomic analysis results of 163 NPC cases, demonstrating that somatostatin receptor 2 (SSTR2) gene expression in EBV‐positive and in EBV‐negative NPC correlated with genomic alterations and an inflamed microenvironment.
Dara Bracken‐Clarke, Elisabetta Xue, Harris Krause, Tolulope Adeyelu, Mark G. Evans, Dilara Akbulut, Martha Quezado, Nishant Gandhi, Alex Farrell, Heloisa P. Soares, Emil Lou, Minh Phan, Rusha Patel, Ari M. Vanderwalde, Andrew Elliott, Conor E. Steuer, Nabil F. Saba, Daniel J. Lubin, Nyall R. London Jr, James L. Gulley, Charalampos S. Floudas   +20 more
wiley   +1 more source

Nanomaterial‐Mediated Radiotherapy–Immunotherapy Combinations: Breaking Immunosuppression and Revolutionizing Cancer Treatment

MedComm – Biomaterials and Applications, Volume 5, Issue 3, September 2026.
Nanomaterials integrate radiotherapy and immunotherapy by enhancing radiosensitivity, remodeling the immunosuppressive tumor microenvironment, and promoting systemic antitumor immunity. This review summarizes the latest strategies of nanomaterial‐mediated combinations (RT, immunotherapy, IRT) and highlights future directions for overcoming clinical ...
Peijie Li, Xiangqin Wang, Sisi He, Hu Ma
wiley   +1 more source

A Care Process Model to Deliver 177Lu-Dotatate Peptide Receptor Radionuclide Therapy for Patients With Neuroendocrine Tumors

Frontiers in Oncology, 2019
Purpose: To develop a care process model for the delivery of peptide receptor radionuclide therapy (PRRT) with lutetium-177 (177Lu)-Dotatate for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs ...
Pashtoon Murtaza Kasi, Catherine L. Maige, Faisal Shahjehan, Jessica M. Rodgers, Debora L. Aloszka, Ashton Ritter, Margaret L. Andrus, Jessica M. Mcmillan, Kabir Mody, Akash Sharma, Manoj K. Jain   +10 more
doaj   +1 more source

Evaluation of the Efficacy of a Combined Treatment Using the mTOR-Inhibitor Everolimus and [177Lu]Lu-DOTA-TATE in Nude CD1 Mice with SSTR-Expressing Pancreatic AR42J Xenograft Tumors

Biomedicines, 2022
Therapy options for advanced pancreatic neuroendocrine tumors (pNETs) include the mTOR inhibitor everolimus and peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-DOTA-TATE, however further optimization in the therapeutic landscape is required ...
Johannes Zellmer, Hsi-Yu Yen, Lena Kaiser, Franz Josef Gildehaus, Guido Böning, Katja Steiger, Marcus Hacker, Peter Bartenstein, Andrei Todica, Alexander R. Haug, Harun Ilhan   +10 more
doaj   +1 more source

HIV drug resistance and treatment success in the Republic of Congo: Implications for optimized treatment

HIV Medicine, Volume 27, Issue 9, Page 1421-1433, September 2026.
Abstract Objectives Increasing rates of HIV‐1 drug resistance (HIVDR) threaten the effectiveness of antiretroviral therapy (ART) programmes in sub‐Saharan Africa, particularly among children, adolescents and young adults, who face limited treatment options.
Dominic Rauschning, Arcy Marcelin Elenga Ike, Johanna Holterhoff, Amira Stockinger, Darrel Ornelle Elion Assiana, Claujens Chastel Mfoutou Mapanguy, Freisnel Hermeland Mouzinga, Carola Horn, Isabelle Suarez, Ferdinand Heyn, Diane Alexia Fila, Hubert Banguissa, Fabien Roch Niama, Donatien Moukassa, Eva Heger, Francine Ntoumi, Clara Lehmann   +16 more
wiley   +1 more source

Peptide Receptor Radionuclide Therapy Using 177Lu-DOTATATE in Advanced Neuroendocrine Tumors (NETs) in a Limited-Resource Environment

World Journal of Nuclear Medicine, 2022
Background This study was conducted to evaluate the clinical efficacy and safety of peptide receptor radionuclide therapy (PRRT) using 177Lu-DOTA0-Tyr3-octreotate (DOTATATE) in patients with neuroendocrine tumors (NETs).
Mohammadreza Kalantarhormozi, Samaneh Hassanzadeh, Seyed Javad Rekabpour, Mohammad Reza Ravanbod, Esmail Jafari, AbdulLatif Amini, Habibollah Dadgar, Mehdi Mahmoudpour, Iraj Nabipour, Narges Jokar, Majid Assadi   +10 more
doaj   +1 more source

177Lu-DOTATATE therapy in metastatic/ inoperable pheochromocytoma-paraganglioma

Endocrine Connections, 2020
Introduction: 177Lu-DOTATATE-based peptide receptor radionuclide therapy (PRRT) is a promising therapy for metastatic and/or inoperable pheochromocytoma and paraganglioma (PPGL).
Sanjeet Kumar Jaiswal, Vijaya Sarathi, Saba Samad Memon, Robin Garg, Gaurav Malhotra, Priyanka Verma, Ravikumar Shah, Manjeet Kaur Sehemby, Virendra A Patil, Swati Jadhav, Anurag Ranjan Lila, Nalini S Shah, Tushar R Bandgar   +12 more
doaj   +1 more source